Novo Nordisk's Japan Unit To Apply For Regulatory Approval Of Stronger Insulin Drugs
This article was originally published in PharmAsia News
Executive Summary
The Japanese unit of Danish drug maker Novo Nordisk plans to apply for Japanese approval of a pair of insulin-injection products it hopes to begin marketing next year. Novo Nordisk Pharma already has NovoRapid 30 Mix on the Japanese market, but the two new versions, also rapid-acting, contain higher amounts of insulin aspart. The new variations are NovoRapid 50 Mix and NovoRapid 70 Mix, which Novo Nordisk Pharma hopes will help stave off nascent competition from other drug makers as Japan deals with rising obesity associated with diabetes. (Click here for more - a subscription may be required